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Growing experimental and clinical evidence suggests that a chronic inflammatory
response induced by gut dysbiosis can critically contribute to the development of
rheumatic diseases, including rheumatoid arthritis (RA). Of interest, an adherence to a
Mediterranean diet has been linked to a reduction in mortality and morbidity in patients
with inflammatory diseases. Diet and intestinal microbiota are modifying factors that
may influence intestinal barrier strength, functional integrity, and permeability regulation.
Intestinal microbiota may play a crucial role in RA pathogenesis, but up to now no
solid data has clarified a mechanistic relationship between gut microbiota and the
development of RA. Nonetheless, microbiota composition in subjects with RA differs from
that of controls and this altered microbiome can be partially restored after prescribing
disease modifying antirheumatic drugs. High levels of Prevotella copri and similar species
are correlated with low levels of microbiota previously associated with immune regulating
properties. In addition, some nutrients can alter intestinal permeability and thereby
influence the immune response without a known impact on the microbiota. However,
critical questions remain to be elucidated, such as the way microbiome fluctuates in
relation to diet, and how disease activity may be influenced by changes in diet, microbiota
or diet-intestinal microbiota equilibrium.
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DIET, MICROBIOTA, AND GUT PERMEABILITY—THE UNKNOWN
TRIAD IN RHEUMATOID ARTHRITIS
A growing body of experimental and clinical evidence suggests that a chronic inflammatory
response induced by gut dysbiosis can critically contribute to the development of a number of
rheumatic diseases, including RA (1–3). Of interest to this discussion, some RA patients suffer
from clinical or subclinical gut disturbances (4). It has been hypothesized that at some point of
the preclinical phase of RA, at the level of the mucosal surface, interactions between microbes,
and other potential environmental factors (e.g., diet, physical, and emotional stress) as well
as host factors lead to mucosal inflammation and to the breaking of immune tolerance. This
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mucosal inflammation may enhance local—and then systemic—
immune disturbances, through mechanisms that may include
molecular mimicry or facilitation of direct autoimmunity to
self-antigens (5, 6). Breaching this single layer of epithelium
can lead to pathological exposure of the highly immunoreactive
subepithelium to foreign antigens in the lumen (4). The
equilibrium between tolerance and immunity to non-
self-antigens can be ruptured by this increased intestinal
permeability, which in many cases may facilitate absorption of
antigens and contribute to the persistence and exacerbation of
some immune mediated diseases, including RA (7).
Two major altering factors that may influence barrier strength
and functional integrity, with an effect in intestinal permeability
regulation, are diet and intestinal microbiota. These factors may
allow the entry of external antigens from the gut lumen into
the host (6, 8, 9). Both are life style related, which suggests
that environmental factors might influence the function of the
intestinal barrier and thus, influence immune health and the
onset and activity of diseases such as RA (9).
Intestinal Microbiota and Rheumatoid
Arthritis
The intestinal tract harbors the largest bacterial community
associated with the human body. Everyone carries up to a
few hundred species of intestinal bacteria (9). Over 90% of
intestinal bacteria belong to the Bacteroidetes and Firmicutes
phyla, but other phyla like Proteobacteria, Actinobacteria,
Fusobacteria, Verrucomicrobia, and Cyanobacteria also play a
crucial role in the maintenance and regulation of homeostasis in
intestinal microflora (3, 7). Among other functions, the intestinal
microbiota is a critical factor for the homeostasis of the host
immune system and as such, any alteration on the gut microbiota
may impact on the host immune response (10, 11).
Human studies revealed that patients with RA display
significant differences of the intestinal microbiota and a
decreased gut microbial diversity in comparison to healthy
controls (3), both related with disease duration and autoantibody
levels (3, 12, 13). Patients with RA, particularly erosive patients,
carry a distinctive enterotype of gut microbiota characterized
by a lower abundance of bacteria belonging to the family
Bifidobacterium and Bacteroides (12, 14, 15) and, at least at early
stages of the disease, an abundance of Prevotella copri (14, 16).
The association between an imbalance of the intestinal
microbiota and RA has been suggested to happen due to different
mechanisms that may impact the host immune system and its
function, including:
(i) the activation of antigen-presenting cells (APCs), such
as the dendritic cells, which can impact the cytokine
production and antigen presentation. Such disturbances
can further modulate the host immune response by,
for instance, impinging on T cells differentiation and
function. These microbiota-induced effects can be mediated
through pathogen recognition receptors, key innate
immune receptors, capable of perceiving pathogen-
associated molecular patterns, such as the toll-like receptors
(TLRs) (10);
(ii) the ability to promote the citrullination of peptides via the
enzymatic action of peptidyl-arginine deiminases (PADs).
Concerning this, it is of interest that the intestinal
epithelium is a major producer of citrulline in the human
body (4). Furthermore, PAD is active in the human intestine
and the intestinal microbiome may also encode active
microbial PADs (4). Thus, the intestine may stand as a
source of citrullinated peptides, along with other mucosal
surfaces. In this respect, peptide citrullination by the
bacterial PAD enzyme expressed by P. gingivalis has been
suggested to strongly contribute for the close association
between periodontitis, an inflammatory disease of the oral
mucosa, with an increased susceptibility to RA (10, 17);
(iii) antigenic mimicry, which can result from similarities
existing between foreign antigens and self-antigens, that
then evoke the activation of pathogen-derived autoreactive
T and B cells and thus lead to autoimmunity (10);
(iv) impact on the permeability of the intestinal mucosal, by
modulating the expression of tight junction (TJ) proteins;
(v) and control of the host immune system. This effect can be
exerted, for instance, by modulating T cells differentiation
and unbalancing the homeostasis between T helper type
17 (Th17) cells and T regulatory (Treg) cells. In RA mice
models, it has been shown that specific alterations in
the intestinal microbiota may favor the pathophysiological
action of Th17 cells in detriment of the suppressive action
of Treg cells, consequently, promoting Th17-mediated
mucosal inflammation (10).
Overall, the elicited immune responses may be dependent on
the presence of certain genera/species. Bacteroides fragilis, for
example, can stimulate Th1-mediated immune responses in
the initial stages of colonization by producing polysaccharide
A. Collinsella sp and may contribute to RA pathogenesis by
increasing gut permeability, lowering the expression of TJ
proteins and influencing the epithelial production of IL-17A
(10, 12). Butyrate producing microbes, such as Clostridia,
Faecalibacteria, and some species of Lachnospiraceae may also
play a crucial role in keeping the integrity of intestinal epithelia,
having a documented anti-inflammatory effect in the context of
rheumatic diseases, including RA (3, 14).
In addition, the idea that the onset of autoimmunity may be
related to gastrointestinal tract is supported not only by the fact
that microbiota composition in subjects with RA differs from
controls, but also by the observation that altered microbiome




Adding an additional level of complexity, it is becoming
increasingly clear that the close interplay between variations in
microbiota composition and RA may not be so simple. As a
paradigmatic example, several conflicting associations have been
observed regarding Prevotella species and RA pathogenesis. In
fact, although some studies in RA patients display an association
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of Prevotella species as a contributive risk factor to the onset
of the disease, contrarily, others have suggested that it may
be protective (10). The existing data sustain that the gut
microbiota of established RA patients exhibits a lower abundance
of Prevotella species (15). However, Scher et al. (18) reported that
individuals with early RA were more likely to harbor Prevotella
copri (PC) compared to controls. Also, Maeda et al. (19) observed
PC in abundance within gut microbiota in Japanese patients
with early RA. According to these authors this species has a
relevant impact on the inflammatory response, by inducing Th17
related cytokines, such as IL-6 and IL-23, and an increase on
the intestinal permeability as well, with influence on bacteria
penetration throughout the body. In addition, high levels of PC
and similar species are correlated with low levels of protective
microbiota, which are believed to regulate the immune system
(20). An abundance of PC in early RA stagesmay very likely stand
as an important mechanism that links dysbiosis with arthritis
pathogenesis (10).
Marietta et al. (16) also focused their attention at the Prevotella
species. In an experimental study they showed that Prevotella
histicola can lead to a lower gut permeability by increasing
the expression of enzymes required to produce antimicrobial
peptides, as well as, of TJ proteins (zonula occludens 1
and occludin). These authors suggest this species to have
immunomodulating properties, by generating Treg cells and
increasing the transcription of interleukin-10 (16).
It is worth noticing that more than 40 different Prevotella
species exist, with a vast and different array of genome repertoires
among strains and between Prevotella species and hosts. This
genetic high diversity found within Prevotella species might
explain the highly different behavior observed when considering
the genus-level identification (18), which possibly explain part
of inconsistences observed when relationship between diet and
health/disease is tested (10, 21). It’s still missing, however, a
question that so far any study has placed, which is of whether
of the same genus are consistently linked to dietary patterns
or equally responsive to diet variations and at a more complex
level, in what manner such relationship may influence the disease
behavior (22).
DIET AND RHEUMATOID ARTHRITIS
Discussion about possible mechanisms by which diet influence
RA, its effect on intestinal microbiota and gut permeability
are also a current hot topic. Literature has been showing
that individual diet content may have an important impact
on microbiota and metabolome expression, thereby influencing
intestinal integrity and permeability (11, 23, 24).
Clustering of the human gut microbiota, designated
enterotypes, was first described in 2011 (25, 26). One of the
largest bacterial groups that can be found in the gut are the
Bacteroidetes. Amongst this phylum, there are a lot of genera
which are diet-responsive. Particularly, the increase in Prevotella
and Bacteroidetes can be associated to a high-fiber diet and to
the consumption of a diet rich in both fat and animal protein,
respectively. (8, 19).
The Bacteroides-driven enterotype is reported to be
predominant in individuals consuming more animal protein and
saturated fats (western diet), becoming clearly that some kind of
nutrients/food may enhance this type of enterotype. In contrast,
the Prevotella-driven enterotype is poorly represented in these
individuals but present at high values in individuals consuming
carbohydrates, simple sugars and fiber, suggesting an association
with a carbohydrate-based diet (8, 27).
The food patterns of the populations who lived around the
Mediterranean sea during the 60’s, inspire what is, nowadays,
commonly known as The Mediterranean Diet (MD), which
is, proven, one of the healthiest dietary pattern existing (28–
30). The essence of this diet consists in the high consumption
of products like fruits, vegetables, legumes, unrefined cereals
and nuts, the moderate consumption of fish, poultry and dairy
products as cheese and yogurt, and the low consumption of red
meat products. Olive oil is used as the main edible-fat source
and wine is consumed in a regular, but moderate, basis (29, 30).
The reduction in overall mortality and morbidity has been linked
to a greater adherence to the MD and this food pattern is
highly proposed as a beneficial dietary approach for patients with
inflammatory diseases (30, 31).
According to some authors, important RA disease
characteristics namely, inflammatory activity disease, physical
function and vitality, may be clinically related to MD pattern,
particularly when compared to a western diet (10, 32). No
association has been proved regarding the susceptibility to
disease, nonetheless. On the Skoldstam’s study (33), after 12
weeks of intervention, patients in the MD group showed a
significant improvement in DAS-28 (Disease Activity Score-−28
joints), HAQ (Health Assessment Questionnaire), whereas
subjects in the control group displayed no significant changes
in these parameters. In another study, developed by Mckellar
et al. (34) and Tedeschi and Costenbader (35), after 6 months,
patient global pain VAS (Visual Analog Scale), and morning
stiffness were significantly improved in the intervention arm
when compared to the control arm (35). It is important to note
that RA disease activity was significantly decrease in patients
with adequate level of typical MD antioxidant as vitamin C,
retinol, and uric acid (32).
An association between MD and short chain fatty acids
(SCFAs) production, is well known and theoretically plausible.
Rich fiber foods such as fruit, vegetables, and legumes, all
regularly consumed by individuals who practice a MD pattern,
have the ability to become degraded by Firmicutes and
Bacteroidetes bacteria, leading to high feacal SCFA (30, 36). Fiber
is the most well-known nutrient with an important impact on
microbiota. Diets rich in this nutrient increase SCFA producing
bacteria, with benefits on intestinal barrier structure (11).
Particularly the butyrate strengthens the barrier by increasing
TJ protein expression and transepithelial electrical resistance
(TER), and by consequently decreasing intestinal permeability
and bacterial translocation. This has been shown to prevent the
activation of effector T cells and to abrogate the manifestation
of undesirable local and systemic inflammatory responses (9, 11,
37). The changes in gut microbial ecology and associated SCFA
driven immune modulation can, in a logical way, explain the
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mechanisms behind clinical amelioration of RA in individuals
exposed to MD. Despite of that, the validation in humans it’s still
needed (36).
Overall, additional research is necessary to elucidate the links
between the health-promoting food pattern of the MD with gut
microbiota characteristics (30).
Four small RCT have also studied the potential benefits of
probiotics in RA. Probiotics are living organisms with a well-
documented range of health benefits, associated not only with
antimicrobial effects, but also to immune system, or with gut
permeability (9, 10, 38, 39). In two small RCTs, Lactobacillus
casei was shown to significantly reduce the expression of pro-
inflammatory cytokines, namely IL-6 and TNF-α, and COX-2




• High-fat diets (48)
• Milk fat (11, 49)
• Fatty acids: capric acid, lauric acid,
long-chain fatty acids,
eicosapentaenoic acid, γ-linoleic
acid, and docosahexaenoic acid
(11, 49)
• Gliadin (50, 51)
• Alcohol (and acetaldehyde; 37)
• Chitosan (52)
• Additives used in food industry:
salt, sugar, emulsifiers and
surfactants, organic solvents, and
microbial transglutaminase (53)
• Vegetables extracts (54)
• Glutamine (55, 56)
• Tryptophan (11)
• Vitamin D (7, 8, 11, 18)
• Polyphenols: quercetin, myricetin,
and kaempferol (57, 58)
• Curcumin (11, 56)
• Zinc (59)
activity, alleviating the manifestations of RA (3, 40, 41). Another
study (42), with an association of probiotics (Lactobacillus
acidophilus, Lactobacillus casei, and Bifidobacterium bifidum)
resulted in improved DAS28 and a lower high sensitivity C-
reactive protein concentrations when compared with placebo.
Another RCT, testing a different Lactobacillus strain (L.
rhamnosus), did not demonstrate any efficacy after one year of
use (32, 43). In addition, several in vivo studies have assayed
the use of probiotics as a therapeutic intervention. Lactobacillus
caseiwas observed to attenuate symptoms in the mouse collagen-
induced arthritis model by changing Th17 cells production,
via no expression of IL-6, IL-17 and IL-23 cytokines (14, 15,
44). Same results were reported when using the Lactobacillus
GG strain in the antigen-induced arthritis model in Lewis
rats (14, 15, 45). Moreover, the use of E.coli Nissle 1917,
Bifidobacterium infantis and Lactobacillus plantarum appears
to have a positive impact on barrier strength with benefits
on expression and production tight junction proteins (6, 9).
By contrast, Lactobacillus bifidus showed a probable ability
to promote joint swelling in germ free mice, by TLR2/TLR4
activation (3, 34, 46). Although these studies have globally
suggested the potential benefits of probiotic supplementation in
RA, until now the evidence is not considered strong enough to
propose the inclusion of probiotic supplements in the diet of RA
patients as part of their disease management strategy (47).
SPECIFIC NUTRIENTS AND GUT
PERMEABILITY
There are also some nutrients that can alter intestinal
permeability and thereby influence the immune response without
a known impact on the microbiota (Table 1). The depletion of
some amino degrade carbohydrates acids like glutamine (55)
FIGURE 1 | Effect of microbiota and diet in RA (onset and its manifestations).
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or tryptophan (11) has been associated with a lower barrier
function, translated in increased gut permeability. Vitamin D
(7, 9, 11, 18) or polyphenols, as quercetin, myricetin, kaempferol,
or curcumin have been shown to participate in the regulation of
the intestinal barrier too, once they promote TER enhancement
and a higher expression of TJ proteins, likeZO-1 and claudin-1.
Also, a depletion of zinc, a micronutrient known to be essential
for cell survival and function, has been shown to increase
intestinal permeability (59). Interestingly most of these nutrients
are commonly abundant in a MD pattern, which as referred
before, is known as a potentially beneficial diet in RA. Apart
from these nutrients, other food compounds, mostly present
at western diets such as fatty acids [specially from high fat
diets; (48)], alcohol (11), additives used in food industry (53),
gliadin [protein present in wheat and several other cereals;
(50, 51)], chitosan (52) or even some food processing methods
using different microbial and fungal strains [that promotes
eventual horizontal gene exchange; (60)], are known to negatively
regulate barrier function via compromising its integrity as they
alter TJ proteins expression and distribution, decrease TER
and favor the growth of pathogenic or opportunistic bacteria
(9, 61).
However, the real-life impact of all these nutrients on the
intestinal permeability and the immune response in RA patients
is still undisclosed (62).
CONCLUSIONS
Overall, it is now known that RA patients display a distinct
gut microbiota composition at the moment of diagnosis in
comparison to healthy individuals. Moreover, the microbiota
composition of RA patients suffers further changes as the
disease progresses. On the other hand, diet, especially the
MD pattern, seems to influence the physiopathology of RA,
potentially lowering disease activity, and improving the outcome
(Figure 1).
However, critical questions remain to be elucidated, keeping
the research agenda active in this field:
1) Are the clinical benefits observed withMD associated with the
selective growth of a “healthy gut microbiota”? This possible
association remains to be documented.
2) What is the relevance of intestinal permeability in this
equation since both diet and microbiota seem to change its
functionality? It is still unclear if intestinal permeability is
directly affected independently by both variables or if the
mechanism is sequential, depending on the influence of diet
on microbioma.
3) How the microbiome fluctuates in relation to diet, and
how disease activity may be influenced by changes in diet,
microbiota or diet-intestinal microbiota equilibrium.
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